Vita Life Sciences Balance Sheet Health

Financial Health criteria checks 6/6

Vita Life Sciences has a total shareholder equity of A$48.7M and total debt of A$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are A$68.0M and A$19.3M respectively. Vita Life Sciences's EBIT is A$12.1M making its interest coverage ratio -13.1. It has cash and short-term investments of A$27.7M.

Key information

Debt to equity ratio

AU$0

Debt

Interest coverage ratio	-13.1x
Cash	AU$27.75m
Equity	AU$48.70m
Total liabilities	AU$19.25m
Total assets	AU$67.95m

Recent financial health updates

No updates

Recent updates

Financial Position Analysis

Short Term Liabilities: VLS's short term assets (A$56.3M) exceed its short term liabilities (A$19.0M).

Long Term Liabilities: VLS's short term assets (A$56.3M) exceed its long term liabilities (A$236.0K).

Debt to Equity History and Analysis

Debt Level: VLS is debt free.

Reducing Debt: VLS has no debt compared to 5 years ago when its debt to equity ratio was 9%.

Debt Coverage: VLS has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: VLS has no debt, therefore coverage of interest payments is not a concern.

Vita Life Sciences Balance Sheet Health

Financial Health criteria checks 6/6

Key information

Recent financial health updates

Recent updates

Non-Executive Chairman recently sold AU$654k worth of stock

New minor risk - Insider selling

MD & Director recently sold AU$1.9m worth of stock

Upcoming dividend of AU$0.06 per share

Vita Life Sciences Limited, Annual General Meeting, May 15, 2024

Final dividend increased to AU$0.06

Full year 2023 earnings released: EPS: AU$0.17 (vs AU$0.13 in FY 2022)

Less than half of directors are independent

Vita Life Sciences Limited Provides Earnings Guidance for the Full Year Ending December 31, 2023

Less than half of directors are independent

Upcoming dividend of AU$0.03 per share at 3.7% yield

Less than half of directors are independent

Vita Life Sciences Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, 6 October 2023

Vita Life Sciences Limited Appoints Peter Osborne as an Independent Non-Executive Director

No independent directors

No independent directors

No independent directors

No independent directors

Full year 2022 earnings released: EPS: AU$0.13 (vs AU$0.16 in FY 2021)

Upcoming dividend of AU$0.033 per share at 3.9% yield

No independent directors

Full year 2022 earnings released: EPS: AU$0.13 (vs AU$0.16 in FY 2021)

No independent directors

No independent directors

No independent directors

No independent directors

Vita Life Sciences Provides Earnings Guidance for the Full Year Ending 31 December 2022

No independent directors

Less than half of directors are independent

Vita Life Sciences Limited Announces Board Changes, Effective 30 September 2022

Upcoming dividend of AU$0.028 per share

Vita Life Sciences Limited Declares Fully Franked Interim Dividend for the Six Months Ended June 30, 2022, Payable on 7 October 2022

First half 2022 earnings released: EPS: AU$0.069 (vs AU$0.07 in 1H 2021)

Less than half of directors are independent

Less than half of directors are independent

Vita Life Sciences Limited Provides Earnings Guidance for the Half Year Ending June 30, 2022

Less than half of directors are independent

Upcoming dividend of AU$0.03 per share

Investor sentiment improved over the past week

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Less than half of directors are independent

Vita Life Sciences Limited Announces Dividend for Six Months Ended December 31, 2021, Payable on April 7, 2022

Less than half of directors are independent

Less than half of directors are independent

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Less than half of directors are independent

Upcoming dividend of AU$0.028 per share

First half 2021 earnings released: EPS AU$0.07 (vs AU$0.058 in 1H 2020)

Less than half of directors are independent

Less than half of directors are independent

Vita Life Sciences Limited Provides Earnings Guidance for the Half Year Ending June 30, 2021

Upcoming Dividend of AU$0.015 Per Share

Earnings released

Financial Position Analysis

Debt to Equity History and Analysis

Balance Sheet

Discover healthy companies